<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: risk factors inherent", fill: "#b768a2"},
{source: "1: risk factors inherent", target: "1: Exactechs ", fill: "#b768a2"},
{source: "1: Exactechs ", target: "1: which should", fill: "#b768a2"},
{source: "1: which should", target: "1: exhaustive statement", fill: "#b768a2"},
{source: "1: exhaustive statement", target: "1: potential risks", fill: "#b768a2"},
{source: "1: potential risks", target: "1: uncertainties", fill: "#b768a2"},
{source: "1: uncertainties", target: "1: government regulation", fill: "#b768a2"},
{source: "1: risk factors inherent", target: "2: government", fill: "#ff0"},
{source: "2: government", target: "2: clearances", fill: "#ff0"},
{source: "2: clearances", target: "2: modifications", fill: "#ff0"},
{source: "2: government", target: "5: faces uncertainty", fill: "#6f00ff"},
{source: "5: faces uncertainty", target: "5: availability", fill: "#6f00ff"},
{source: "5: availability", target: "5: thirdparty", fill: "#6f00ff"},
{source: "5: thirdparty", target: "5: reimbursement", fill: "#6f00ff"},
{source: "5: faces uncertainty", target: "6: failure by physicians hospitals", fill: "#343434"},
{source: "6: failure by physicians hospitals", target: "6: Exactechs ", fill: "#343434"},
{source: "6: Exactechs ", target: "6: sufficient reimbursement from", fill: "#343434"},
{source: "6: sufficient reimbursement from", target: "6: reimbursement", fill: "#343434"},
{source: "6: reimbursement", target: "6: health care payors", fill: "#343434"},
{source: "6: health care payors", target: "6: Exactechs ", fill: "#343434"},
{source: "6: Exactechs ", target: "6: governmental", fill: "#343434"},
{source: "6: governmental", target: "6: private payors policies toward", fill: "#343434"},
{source: "6: private payors policies toward", target: "6: such procedures could", fill: "#343434"},
{source: "6: such procedures could", target: "6: Exactechs ", fill: "#343434"},
{source: "6: failure by physicians hospitals", target: "7: relatively high levels", fill: "#bd33a4"},
{source: "7: relatively high levels", target: "9: the Companys ", fill: "#cb6d51"},
{source: "9: the Companys ", target: "9: inventory becomes obsolete", fill: "#cb6d51"},
{source: "9: inventory becomes obsolete", target: "9: Exactechs ", fill: "#cb6d51"},
{source: "9: Exactechs ", target: "9: earnings due", fill: "#cb6d51"},
{source: "9: earnings due", target: "9: costs associated with", fill: "#cb6d51"},
{source: "9: costs associated with", target: "9: inventory impairment charges", fill: "#cb6d51"},
{source: "9: the Companys ", target: "11: availability", fill: "#f8de7e"},
{source: "11: availability", target: "11: services become", fill: "#f8de7e"},
{source: "11: services become", target: "11: such increases significantly", fill: "#f8de7e"},
{source: "11: such increases significantly", target: "11: in the Exactechs ", fill: "#f8de7e"},
{source: "11: in the Exactechs ", target: "11: earnings due", fill: "#f8de7e"},
{source: "11: earnings due", target: "11: increased costs", fill: "#f8de7e"},
{source: "11: availability", target: "13: orthopaedic implant industry", fill: "#faebd7"},
{source: "13: orthopaedic implant industry", target: "13: competition", fill: "#faebd7"},
{source: "13: competition", target: "13: areas product", fill: "#faebd7"},
{source: "13: areas product", target: "13: design innovation service", fill: "#faebd7"},
{source: "13: design innovation service", target: "13: hospitals strength", fill: "#faebd7"},
{source: "13: hospitals strength", target: "13: distribution network", fill: "#faebd7"},
{source: "13: orthopaedic implant industry", target: "14: faces competition", fill: "#013220"},
{source: "14: faces competition", target: "14: regional sales representatives within", fill: "#013220"},
{source: "14: regional sales representatives within", target: "14: medical community", fill: "#013220"},
{source: "14: faces competition", target: "16: Exactechs ", fill: "#de3163"},
{source: "16: Exactechs ", target: "16: partially dependent upon", fill: "#de3163"},
{source: "16: partially dependent upon", target: "16: successfully market new", fill: "#de3163"},
{source: "16: successfully market new", target: "16: improved products", fill: "#de3163"},
{source: "16: improved products", target: "16: market acceptance", fill: "#de3163"},
{source: "16: Exactechs ", target: "21: regulators may challenge", fill: "#f78fa7"},
{source: "21: regulators may challenge", target: "21: Exactechs ", fill: "#f78fa7"},
{source: "21: Exactechs ", target: "21: future activities under", fill: "#f78fa7"},
{source: "21: future activities under", target: "21: laws which would", fill: "#f78fa7"},
{source: "21: laws which would", target: "21: could increase", fill: "#f78fa7"},
{source: "21: could increase", target: "21: costs reduce", fill: "#f78fa7"},
{source: "21: costs reduce", target: "21: cash flows", fill: "#f78fa7"},
{source: "21: regulators may challenge", target: "22: patents on specific designs", fill: "#ffef00"},
{source: "22: patents on specific designs", target: "22: relies on", fill: "#ffef00"},
{source: "22: relies on", target: "22: trade secrets", fill: "#ffef00"},
{source: "22: trade secrets", target: "22: proprietary knowhow", fill: "#ffef00"},
{source: "22: patents on specific designs", target: "23: cannot provide assurance as", fill: "#18453b"},
{source: "23: cannot provide assurance as", target: "23: protection which existing", fill: "#18453b"},
{source: "23: protection which existing", target: "23: future patents", fill: "#18453b"},
{source: "23: future patents", target: "23: confidential", fill: "#18453b"},
{source: "23: confidential", target: "23: proprietary", fill: "#18453b"},
{source: "23: proprietary", target: "23: agreements will", fill: "#18453b"},
{source: "23: agreements will", target: "23: parties from whom", fill: "#18453b"},
{source: "23: parties from whom", target: "23: patent rights proprietary", fill: "#18453b"},
{source: "23: patent rights proprietary", target: "23: patent rights", fill: "#18453b"},
{source: "23: patent rights", target: "23: technology", fill: "#18453b"},
{source: "23: technology", target: "23: Exactechs ", fill: "#18453b"},
{source: "23: Exactechs ", target: "23: trade secrets", fill: "#18453b"},
{source: "23: trade secrets", target: "23: proprietary knowhow will", fill: "#18453b"},
{source: "23: proprietary knowhow will", target: "23: otherwise become known", fill: "#18453b"},
{source: "23: otherwise become known", target: "23: independently", fill: "#18453b"},
{source: "23: independently", target: "23: by competitors", fill: "#18453b"},
{source: "23: cannot provide assurance as", target: "26: potential product liability risks which", fill: "#c23b22"},
{source: "26: potential product liability risks which", target: "26: design marketing", fill: "#c23b22"},
{source: "26: design marketing", target: "26: orthopaedic implants", fill: "#c23b22"},
{source: "26: orthopaedic implants", target: "26: surgical instrumentation", fill: "#c23b22"},
{source: "26: potential product liability risks which", target: "29: inability", fill: "#8b8589"},
{source: "29: inability", target: "29: adequate levels", fill: "#8b8589"},
{source: "29: adequate levels", target: "29: product liability insurance coverage on", fill: "#8b8589"},
{source: "29: inability", target: "34: function as designed", fill: "#5f9ea0"},
{source: "34: function as designed", target: "34: designed improperly", fill: "#5f9ea0"},
{source: "34: designed improperly", target: "34: party manufacturer", fill: "#5f9ea0"},
{source: "34: party manufacturer", target: "34: products may choose", fill: "#5f9ea0"},
{source: "34: products may choose", target: "34: forced by", fill: "#5f9ea0"},
{source: "34: forced by", target: "34: regulatory agencies", fill: "#5f9ea0"},
{source: "34: regulatory agencies", target: "34: Contents ", fill: "#5f9ea0"},
{source: "34: Contents ", target: "34: withdraw such products from", fill: "#5f9ea0"},
{source: "34: function as designed", target: "35: patients suffer", fill: "#20b2aa"},
{source: "35: patients suffer", target: "35: function as designed", fill: "#20b2aa"},
{source: "35: function as designed", target: "35: inappropriate", fill: "#20b2aa"},
{source: "35: inappropriate", target: "35: lawsuits seeking", fill: "#20b2aa"},
{source: "35: lawsuits seeking", target: "35: significant compensatory", fill: "#20b2aa"},
{source: "35: significant compensatory", target: "35: punitive damages", fill: "#20b2aa"},
{source: "35: patients suffer", target: "36: product recall", fill: "#00416a"},
{source: "36: product recall", target: "36: seeking significant monetary damages may", fill: "#00416a"},
{source: "36: seeking significant monetary damages may", target: "36: operations", fill: "#00416a"},
{source: "36: operations", target: "36: financial condition", fill: "#00416a"},
{source: "36: product recall", target: "START_HERE", fill: "#00416a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Safety_integrity_level">Safety integrity level</a></td>
      <td>Safety integrity level (SIL) is defined as a relative levels of risk-reduction provided by a safety function, or to specify a target level of risk reduction. In simple terms, SIL is a measurement of performance required for a safety instrumented function (SIF).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_entry_strategy">Market entry strategy</a></td>
      <td>Market entry strategy is a planned distribution and delivery method of goods or services to a new target market.  In the import and export of services, it refers to the creation, establishment, and management of contracts in a foreign country.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Systematic_risk">Systematic risk</a></td>
      <td>In finance and economics, systematic risk (in economics often called aggregate risk or undiversifiable risk) is vulnerability to events which affect aggregate outcomes such as broad market returns, total economy-wide resource holdings, or aggregate income. In many contexts, events like earthquakes, epidemics and major weather catastrophes pose aggregate risks that affect not only the distribution but also the total amount of resources.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/University_of_Florida">University of Florida</a></td>
      <td>The University of Florida (Florida or UF) is a public land-grant research university in Gainesville, Florida. It is a senior member of the State University System of Florida, traces its origins to 1853, and has operated continuously on its Gainesville campus since September 1906.After the Florida state legislature's creation of performance standards in 2013, the Florida Board of Governors designated the University of Florida as a "preeminent university".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lahore_Resolution">Lahore Resolution</a></td>
      <td>The Lahore Resolution (Urdu: قراردادِ لاہور, Qarardad-e-Lahore; Bengali: লাহোর প্রস্তাব, Lahor Prostab), also called Pakistan resolution or declaration of independence of Pakistan, was written and prepared by Muhammad Zafarullah Khan and was presented by A. K. Fazlul Huq, the Prime Minister of Bengal, was a formal political statement adopted by the All-India Muslim League on the occasion of its three-day general session in Lahore on 22–24 March 1940. The resolution called for independent states as seen by the\nstatement:That geographically contiguous units are demarcated regions which should be constituted, with such territorial readjustments as may be necessary that the areas in which the Muslims are numerically in a majority as in the North Western and Eastern Zones of (British) India should be grouped to constitute ‘independent states’ in which the constituent units should be autonomous and sovereign.Although the name "Pakistan" had been proposed by Choudhary Rahmat Ali in his Pakistan Declaration, it was not until after the resolution that it began to be widely used.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/DMG_Clearances">DMG Clearances</a></td>
      <td>DMG Clearances, Inc is a company based in Hockessin, Delaware, USA, which handles music clearances and licensing for the entertainment industry. DMG Clearances was founded in 1996 by Deborah Mannis-Gardner.The company clears musical compositions for use in films, video games, sampling and Broadway Theater.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Availability_heuristic">Availability heuristic</a></td>
      <td>The availability heuristic, also known as availability bias, is a mental shortcut that relies on immediate examples that come to a given person's mind when evaluating a specific topic, concept, method or decision. The availability heuristic operates on the notion that if something can be recalled, it must be important, or at least more important than alternative solutions which are not as readily recalled.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/University_of_Phoenix">University of Phoenix</a></td>
      <td>University of Phoenix (UoPX) is a private for-profit university headquartered in Phoenix, Arizona. Founded in 1976, the university confers certificates and degrees at the certificate, associate, bachelor's, master's, and doctoral degree levels.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Vaccination_policy">Vaccination policy</a></td>
      <td>Vaccination policy is a health policy that governments adopt in order to prevent the spread of infectious disease through vaccination. A wide variety of vaccination policies have been developed over the approximately two centuries since the invention of vaccination with the purpose of creating herd immunity, or eradicating a disease altogether, for the population the government aims to protect.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treacle">Treacle</a></td>
      <td>Treacle () is any uncrystallised syrup made during the refining of sugar. The most common forms of treacle are golden syrup, a pale variety, and a darker variety known as black treacle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2-Arachidonoylglycerol">2-Arachidonoylglycerol</a></td>
      <td>2-Arachidonoylglycerol (2-AG) is an endocannabinoid, an endogenous agonist of the CB1 receptor and the primary endogenous ligand for the CB2 receptor. It is an ester formed from the omega-6 fatty acid arachidonic acid and glycerol.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lead–acid_battery">Lead–acid battery</a></td>
      <td>The lead–acid battery is a type of rechargeable battery first invented in 1859 by French physicist Gaston Planté. It is the first type of rechargeable battery ever created.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_service">Customer service</a></td>
      <td>Customer service is the provision of service to customers before, during, and after a purchase. This makes it an important part of the value chain of clients.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_community_colleges_in_the_United_States_with_campus_housing">List of community colleges in the United States with campus housing</a></td>
      <td>Most community colleges in the United States do not offer on-campus housing for students. These institutions were established primarily to provide low-cost education for students who commute from their homes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Implant_(medicine)">Implant (medicine)</a></td>
      <td>An implant is a medical device manufactured to replace a missing biological structure, support a damaged biological structure, or enhance an existing biological structure. Medical implants are man-made devices, in contrast to a transplant, which is a transplanted biomedical tissue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/DePuy_Synthes">DePuy Synthes</a></td>
      <td>DePuy Synthes () is a franchise of orthopaedic and neurosurgery companies. Acquired by Johnson &amp; Johnson in 1998, its companies form part of the Johnson &amp; Johnson Medical Devices group.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teaching_Hospital,_Peradeniya">Teaching Hospital, Peradeniya</a></td>
      <td>Teaching Hospital, Peradeniya, is one of the three hospitals in Peradeniya, Sri Lanka. It is one of the leading community teaching hospitals in Sri Lanka, affiliated with the University of Peradeniya.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Wally_Uihlein">Wally Uihlein</a></td>
      <td>Wally Uihlein (born 1949) in Haverhill, Massachusetts is a retired president and chief executive officer of the Acushnet Company, which comprises the golf brands Titleist, FootJoy, Pinnacle, and Scotty Cameron.\nThe Acushnet Company is publicly traded (NYSE) with a majority share owned by Fila Korea\nUihlein (pronounced "EE-Line") attended the University of Massachusetts Amherst and completed graduate courses in business management at Suffolk University in Boston.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ignaz_Semmelweis">Ignaz Semmelweis</a></td>
      <td>Ignaz Philipp Semmelweis (German: [ˈɪɡnaːts ˈzɛml̩vaɪs]; Hungarian: Semmelweis Ignác Fülöp [ˈsɛmmɛlvɛjs ˈiɡnaːts ˈfyløp]; 1 July 1818 – 13 August 1865) was a Hungarian physician and scientist, now known as an early pioneer of antiseptic procedures. Described as the "saviour of mothers", Semmelweis discovered that the incidence of puerperal fever (also known as "childbed fever") could be drastically cut by the use of hand disinfection in obstetrical clinics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Journal_of_Cleaner_Production">Journal of Cleaner Production</a></td>
      <td>The Journal of Cleaner Production is a peer-reviewed academic journal covering transdisciplinary research on cleaner production. It is published by Elsevier.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Future_Internet">Future Internet</a></td>
      <td>Future Internet is a general term for research activities on new architectures for the  Internet.\n\n\n== History ==\nWhile the technical development of the Internet was an extensive research topic from the beginning, an increased public awareness of several critical shortcomings in terms of performance, reliability, scalability, security and many other categories  including societal, economical and business aspects, led to future Internet research efforts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pelvic_thrust">Pelvic thrust</a></td>
      <td>The pelvic thrust is the thrusting motion of the pelvic region, which is used for a variety of activities, such as dance or sexual activity.\n\n\n== Sexual activity ==\n\nThe pelvic thrust is used during copulation by many species of mammals, including humans, or for other sexual activities (such as non-penetrative sex).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent_attorney">Patent attorney</a></td>
      <td>A patent attorney is an attorney who has the specialized qualifications necessary for representing clients in obtaining patents and acting in all matters and procedures relating to patent law and practice, such as filing patent applications and oppositions to granted patents. The term is used differently in different countries, and thus may or may not require the same legal qualifications as a general legal practitioner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Rely">Rely</a></td>
      <td>A relay is an electrically operated switch.  It consists of a set of input terminals for a single or multiple control signals, and a set of operating contact terminals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Directive_on_the_Protection_of_Trade_Secrets">Directive on the Protection of Trade Secrets</a></td>
      <td>The Directive (EU) 2016/943 on the protection of undisclosed know-how and business information (trade secrets) against their unlawful acquisition, use and disclosure is a Directive of the European Parliament and the European Council which was adopted by the European Council on 27 May 2016 following an agreement reached with the European Parliament on 15 December 2015 and amendment by the Parliament on 14 March 2016.The aim of the directive is "to harmonise the existing diverging national laws [within the EU] on the protection against the misappropriation of trade secrets, so that companies can exploit and share their trade secrets with privileged business partners across the Internal Market, turning their innovative ideas into growth and jobs".EU member states are required to "bring into force the laws, regulations and administrative provisions necessary to comply with this Directive" within two years i.e. by May 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Four_Agreements">The Four Agreements</a></td>
      <td>The Four Agreements: A Practical Guide to Personal Freedom is a self-help book by bestselling author Don Miguel Ruiz with Janet Mills. The book offers a code of conduct claiming to be based on ancient Toltec wisdom that advocates freedom from self-limiting beliefs that may cause suffering and limitation in a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Glossary_of_patent_law_terms">Glossary of patent law terms</a></td>
      <td>This is a list of legal terms relating to patents. A patent is not a right to practice or use the invention, but a territorial right to exclude others from commercially exploiting the invention, granted to an inventor or his successor in rights in exchange to a public disclosure of the invention.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mood_disorder">Mood disorder</a></td>
      <td>A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and behavioral disorder where a disturbance in the person's mood is the main underlying feature. The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Boston_Scientific">Boston Scientific</a></td>
      <td>Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.\nBoston Scientific is primarily known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ecosystem">Ecosystem</a></td>
      <td>An ecosystem (or ecological system) consists of all the organisms and the physical environment with which they interact.: 458  These biotic and abiotic components are linked together through nutrient cycles and energy flows. Energy enters the system through photosynthesis and is incorporated into plant tissue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Command_center">Command center</a></td>
      <td>A command center (often called a war room) is any place that is used to provide centralized command for some purpose.\nWhile frequently considered to be a military facility, these can be used in many other cases by governments or businesses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Forced-air">Forced-air</a></td>
      <td>A forced-air  central heating system is one which uses air as its heat transfer medium. These systems rely on ductwork, vents, and plenums as means of air distribution, separate from the actual heating and air conditioning systems.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Witzelsucht">Witzelsucht</a></td>
      <td>Witzelsucht (German: [ˈvɪtsl̩ˌzʊxt] "joking addiction") is a set of pure and rare neurological symptoms characterized by a tendency to make puns, or tell inappropriate jokes or pointless stories in socially inappropriate situations. It makes one unable to read sarcasm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/English_defamation_law">English defamation law</a></td>
      <td>Modern libel and slander laws in many countries are originally descended from English defamation law. The history of defamation law in England is somewhat obscure; civil actions for damages seem to have been relatively frequent as far back as the Statute of Gloucester in the reign of Edward I (1272–1307),.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Misrepresentation">Misrepresentation</a></td>
      <td>In common law jurisdictions, a misrepresentation is a false or misleading  statement of fact made during negotiations by one party to another, the statement then inducing that other party to enter into a contract. The misled party may normally rescind the contract, and sometimes may be awarded damages as well (or instead of rescission).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>EXACTECH INC      ITEM 1A RISK FACTORS        Although it is not possible to predict or identify all <font color="blue">risk factors inherent</font>     in Exactech’s business, they may include those listed below, <font color="blue">which should</font>     not  be  considered an <font color="blue">exhaustive statement</font> of all <font color="blue">potential risks</font> and     <font color="blue">uncertainties</font>:           •   Exactech is subject to extensive <font color="blue"><font color="blue">government</font> regulation</font></td>
    </tr>
    <tr>
      <td>Failure to     obtain <font color="blue">government</font> approvals and <font color="blue">clearances</font> for new products and/or     <font color="blue">modifications</font> to existing products on a timely basis would likely have a     material adverse effect on the business and financial results of Exactech</td>
    </tr>
    <tr>
      <td>A     <font color="blue">significant recall</font> of one or more of Exactech’s <font color="blue">products could</font> have a     material adverse effect on Exactech’s business and financial results</td>
    </tr>
    <tr>
      <td>Exactech <font color="blue">cannot provide assurance</font> that such <font color="blue">clearances</font> will be granted or     that review by <font color="blue">government</font> authority will not <font color="blue">involve delays</font> that could     <font color="blue">materially adversely</font> effect Exactech’s revenues and earnings</td>
    </tr>
    <tr>
      <td>•   Exactech <font color="blue">faces uncertainty</font> relating to the <font color="blue">availability</font> of third-party     <font color="blue">reimbursement</font> for its products</td>
    </tr>
    <tr>
      <td>The failure by physicians, hospitals and     other users of Exactech’s products to obtain sufficient <font color="blue">reimbursement</font> from     <font color="blue">health care payors</font> for procedures in which Exactech’s products are used or     adverse changes in <font color="blue">government</font>al and private payors’ policies toward     <font color="blue">reimbursement</font> for <font color="blue">such procedures could</font> have a material adverse effect on     Exactech’s revenues and earnings</td>
    </tr>
    <tr>
      <td>•   Exactech is required to incur significant expenditures of resources in     order to maintain <font color="blue">relatively high levels</font> of inventory</td>
    </tr>
    <tr>
      <td>As a result of the     need to maintain substantial levels of inventory, Exactech is subject to the     risk of <font color="blue">inventory obsolescence</font></td>
    </tr>
    <tr>
      <td>In the event that a substantial portion of     the Company’s <font color="blue">inventory becomes obsolete</font>, it could have a material adverse     effect on Exactech’s <font color="blue">earnings due</font> to the resulting <font color="blue">costs associated with</font> the     <font color="blue">inventory impairment charges</font></td>
    </tr>
    <tr>
      <td>11     ______________________________________________________________________    [36]Table of <font color="blue">Contents       </font>  •   Exactech <font color="blue">relies upon third party suppliers</font> for its <font color="blue">raw materials</font> and     supplies</td>
    </tr>
    <tr>
      <td>Should the <font color="blue">availability</font> and on time delivery of <font color="blue">raw materials</font> and     supplies needed in the production of its products and <font color="blue">services become</font>     unreliable or the costs of <font color="blue">such increases significantly</font>, it could have a     material adverse effect on Exactech’s <font color="blue">earnings due</font> to the resulting     <font color="blue">increased costs</font> of production</td>
    </tr>
    <tr>
      <td>•   Exactech conducts business in a <font color="blue">highly competitive industry</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">orthopaedic implant industry</font> is subject to <font color="blue">competition</font> in the following     areas: product features and design, innovation, service, the ability to     maintain new product flow, relationships with key orthopaedic surgeons and     hospitals, strength of <font color="blue">distribution network</font>, and price</td>
    </tr>
    <tr>
      <td>In addition,     Exactech faces <font color="blue">competition</font> for <font color="blue">regional sales representatives within</font> the     <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Exactech <font color="blue">cannot provide assurance</font> that it will be able to     <font color="blue">compete successfully</font></td>
    </tr>
    <tr>
      <td>•   Exactech’s success is <font color="blue">partially dependent upon</font> its ability to     <font color="blue">successfully market new</font> and <font color="blue">improved products</font> and the <font color="blue">market acceptance</font> of     those products</td>
    </tr>
    <tr>
      <td>The failure of its products to gain <font color="blue">market acceptance</font> would     be likely to have a material adverse effect on its revenues and earnings</td>
    </tr>
    <tr>
      <td>Exactech <font color="blue">cannot provide assurance</font> that new or <font color="blue">improved products</font> will gain     <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>•   Exactech is subject to federal anti-kickback laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>These laws and <font color="blue">regulations</font> prohibit any knowing and willful offer, payment,     <font color="blue">solicitation</font> or receipt of any form of remuneration, either directly or     <font color="blue">indirectly</font>, in return for, or to induce: referral of an individual for a     service or product for <font color="blue">which payment may</font> be made by Medicare, Medicaid or     another <font color="blue">government</font> sponsored health care program, or purchasing, leasing,     ordering or arranging for, or <font color="blue">recommending</font> the purchase, lease or order of,     any service or product for <font color="blue">which payment may</font> be made by a     <font color="blue">government</font>-sponsored health care program</td>
    </tr>
    <tr>
      <td>Those <font color="blue">regulators may challenge</font> or     review Exactech’s current or <font color="blue">future activities under</font> these laws, which would     be costly and time consuming, and <font color="blue">could increase</font> operating costs, reduce     revenues and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>•   Exactech holds <font color="blue">patents on specific designs</font> and processes and <font color="blue">relies on</font>     <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> know-how</td>
    </tr>
    <tr>
      <td>Exactech <font color="blue">cannot provide assurance</font> as     to the breadth or degree of <font color="blue">protection which existing</font> or <font color="blue">future patents</font>, if     any, may afford the Company, that those <font color="blue">confidential</font> or <font color="blue">proprietary</font>     information <font color="blue">agreements will</font> not be breached, that the <font color="blue">parties from whom</font>     Exactech has licensed or otherwise acquired <font color="blue">patent rights</font>, <font color="blue">proprietary</font>     rights and <font color="blue">technology</font> have full rights to those <font color="blue">patent rights</font> and     <font color="blue">technology</font>, or that Exactech’s <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> know-how will     not <font color="blue">otherwise become known</font> to or <font color="blue">independently</font> developed <font color="blue">by competitors</font></td>
    </tr>
    <tr>
      <td>•   Exactech must devote substantial resources to research and     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Exactech <font color="blue">cannot provide assurance</font> that it will be successful in     developing competitive new products and/or improving existing products so     that its <font color="blue">products remain competitive</font> and <font color="blue">avoid obsolescence</font></td>
    </tr>
    <tr>
      <td>•   Exactech is subject to potential product <font color="blue">liability</font> risks, which are     inherent in the design, marketing and sale of <font color="blue">orthopaedic implants</font> and     <font color="blue">surgical instrumentation</font></td>
    </tr>
    <tr>
      <td>Exactech <font color="blue">cannot provide assurance</font> it will not face     claims resulting in substantial <font color="blue">liability</font> for which Exactech is not fully     insured</td>
    </tr>
    <tr>
      <td>A partially or <font color="blue">completely uninsured successful</font> claim against     Exactech of sufficient magnitude could have a material adverse effect on     Exactech’s earnings and <font color="blue">cash flows</font> due the cost of <font color="blue">defending itself against</font>     such a claim</td>
    </tr>
    <tr>
      <td>•   Exactech is subject to the risk of an <font color="blue">inability</font> to secure and maintain     <font color="blue">adequate levels</font> of product <font color="blue">liability</font> insurance coverage on acceptable terms</td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> insurance premiums are volatile</td>
    </tr>
    <tr>
      <td>Should <font color="blue">premiums continue</font>     to increase significantly, it could have a material adverse effect on     Exactech’s earnings and <font color="blue">cash flows</font> due to the increase in operating costs     that would result</td>
    </tr>
    <tr>
      <td>•   Exactech’s products, including products that are <font color="blue">manufactured by third</font>     parties but distributed by us, may be subject to recall or product <font color="blue">liability</font>     claims</td>
    </tr>
    <tr>
      <td>These products are used in <font color="blue">medical contexts</font> in which it is important     that those <font color="blue">products function with precision</font> and accuracy</td>
    </tr>
    <tr>
      <td>If these products     do not <font color="blue">function as designed</font>, or are <font color="blue">designed improperly</font>, we or the third     <font color="blue">party manufacturer</font> of these <font color="blue">products may choose</font> to or be <font color="blue">forced by</font>     <font color="blue">regulatory agencies</font> to                                           12     ______________________________________________________________________    [37]Table of <font color="blue">Contents       </font><font color="blue">withdraw such products from</font> the market</td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue">patients suffer</font>     injury as a result of any failure of these products to <font color="blue">function as designed</font>,     or  an  <font color="blue">inappropriate</font>  design, we could be subject to <font color="blue">lawsuits seeking</font>     <font color="blue">significant compensatory</font> and <font color="blue">punitive damages</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">product recall</font> or lawsuit     <font color="blue">seeking significant monetary damages may</font> have a material adverse effect on     our business, <font color="blue">operations</font> or <font color="blue">financial condition</font></td>
    </tr>
  </tbody>
</table>